上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 二○二五年第二次临时股东大会的 法律意见书 地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 二○二五年第二次临时股东大会的 法律意见书 致：湖北亨迪药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受湖北亨迪药业 股份有限公司（以下简称"公司"）委托，委派本律师通过远程视频方式出席公 司二○二五年第二次临时股东大会（以下简称"本次股东大会"）。本律师根据《中 华人民共和国公司法》（以下简称《公司法》）等法律、法规、规章和其他规范性 文件以及《湖北亨迪药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核 ...

Core Viewpoint - Hendi Pharmaceutical has obtained the drug registration certificate for Ibuprofen suspension from the National Medical Products Administration as of June 2025, and is currently preparing for product launch and sales [1] Company Developments - The company is actively working on the preliminary preparations for the product's market launch following the receipt of the registration certificate [1] - The impact of the product registration on the company's operating performance is not expected to be significant in the short term [1] Market Considerations - Future revenue generation from the product is uncertain due to factors such as non-uniqueness of the product, competition from similar products, and the effectiveness of the company's business promotion and sales scale [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride [2] Group 1 - The approval is for the chemical raw material drug Methoclopramide Hydrochloride [2]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has recently announced the approval of its application for Methoclopramide Hydrochloride [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211) announced the receipt of the approval notice for Methoclopramide Hydrochloride from the National Medical Products Administration [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methochlorpromazine Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility for improving dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the approval of Methochlorpromazine Hydrochloride, indicating a significant milestone in its product development pipeline [1] - The drug is primarily indicated for the treatment of nausea and vomiting, which could enhance the company's portfolio in the gastrointestinal therapeutic area [1] Industry Summary - The approval of Methochlorpromazine Hydrochloride reflects ongoing regulatory support for new pharmaceutical products in the market, highlighting the importance of innovative treatments for common gastrointestinal issues [1] - The use of dopamine receptor antagonists in managing gastrointestinal symptoms underscores the growing demand for effective therapies in this segment [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Metoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the receipt of a marketing approval notification for Metoclopramide Hydrochloride [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-041 湖北亨迪药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于盐酸甲氧氯普胺（以下简称"药品"）的《化学原料药上 市申请批准通知书》（证书编号：2025YS00820）。现将有关情况公告如下： 一、药品的基本情况 药品名称：盐酸甲氧氯普胺 登记号：Y20230001040 规格：12kg/桶 四、风险提示 由于医药产品的销售受国家政策、市场需求、同类型药品市场竞争等因素的 影响，未来该产品销售情况存在不确定性，敬请广大投资者谨慎决策，注意防范 投资风险。 生产企业：湖北亨迪药业股份有限公司 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品的其他相关情况 盐酸甲氧氯普胺是一种多巴胺受体拮抗剂，主要用于缓解恶心、呕 ...

Group 1 - The core point of the article is that Hendi Pharmaceutical announced the approval of several proposals, including changes to the company's registered capital and amendments to the company’s articles of association [2] Group 2 - The second meeting of the second board of directors was held on the evening of September 2, where the proposals were reviewed and approved [2] - The company will proceed with the necessary business registration changes following the approval of the proposals [2]

Group 1 - The company, Hendi Pharmaceutical, announced that it will hold its second extraordinary general meeting of shareholders on September 18, 2025 [2] - The agenda for the meeting includes proposals to change the company's registered capital, amend the articles of association, and handle business registration changes [2] - Additionally, the meeting will review proposals to revise certain governance systems of the company [2]